Ondřej Vaněk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ondřej Vaněk has a total of 533 co-authors. Here are the top co-authors by number of shared publications:
Karel Bezouška
15 shared publications- Daniel Kavan
Department of Biochemistry, Faculty of Science, Charles University
13 shared publications - Kateřina Hofbauerová
Institute of Microbiology, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague, Czech Republic
12 shared publications - Jan Bláha
Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
10 shared publications - Barbora Kalousková
Institute of Applied Physics, TU Wien, Wiedner Hauptstr. 8-10, 1040 Vienna, Austria
9 shared publications Jan Dohnálek
9 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (11)
EXPERT: A practical and forward-looking guide to capturing protein expression and purification metadata to develop machine learning models
- 29 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (11)
Open AccessEXPERT: A practical and forward-looking guide to capturing protein expression and purification metadata to develop machine learning models
- Open Access
- 29 September 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (10) , 4799-4810
Engineering a Functional Histidine Brace Copper-Binding Site into a De Novo -Designed Protein Scaffold
De novo metalloprotein design has contributed to tremendous advances in bioinorganic chemistry by allowing the manufacturing of proteins with unique structures and functionalities that go beyond evolutionary constraints. Among the array of metal sites that can be engineered within de novo scaffolds, the design of catalytic copper centers is particularly challenging but still harder to achieve due to the versatile coordination environment and redox properties of the copper ion. Here, we present miniLPMO, a fully de novo protein, incorporating a functional histidine brace copper-binding site. Starting from a four-helix-bundle scaffold based on the designed homodimeric α2D protein, our design has integrated rational and computational strategies to optimize coordination shell residues. Circular dichroism and analytical ultracentrifugation experiments indicate that the folding and dimerization state is driven by copper binding. A detailed characterization by UV–Vis and EPR revealed that miniLPMO replicates the spectroscopic features of natural histidine brace sites. Finally, the designed metalloprotein catalyzes the cleavage of glycosidic bonds upon hydrogen peroxide activation, mimicking the activity of natural lytic polysaccharide monooxygenases (LPMOs). This study establishes the feasibility of integrating peculiar catalytic metal-binding sites into scaffolds unrelated to the native protein and designed entirely from scratch.
- 29 September 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (10) , 4799-4810
Open AccessEngineering a Functional Histidine Brace Copper-Binding Site into a De Novo -Designed Protein Scaffold
De novo metalloprotein design has contributed to tremendous advances in bioinorganic chemistry by allowing the manufacturing of proteins with unique structures and functionalities that go beyond evolutionary constraints. Among the array of metal sites that can be engineered within de novo scaffolds, the design of catalytic copper centers is particularly challenging but still harder to achieve due to the versatile coordination environment and redox properties of the copper ion. Here, we present miniLPMO, a fully de novo protein, incorporating a functional histidine brace copper-binding site. Starting from a four-helix-bundle scaffold based on the designed homodimeric α2D protein, our design has integrated rational and computational strategies to optimize coordination shell residues. Circular dichroism and analytical ultracentrifugation experiments indicate that the folding and dimerization state is driven by copper binding. A detailed characterization by UV–Vis and EPR revealed that miniLPMO replicates the spectroscopic features of natural histidine brace sites. Finally, the designed metalloprotein catalyzes the cleavage of glycosidic bonds upon hydrogen peroxide activation, mimicking the activity of natural lytic polysaccharide monooxygenases (LPMOs). This study establishes the feasibility of integrating peculiar catalytic metal-binding sites into scaffolds unrelated to the native protein and designed entirely from scratch.
- Open Access
- 25 September 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (11) , 5367-5380
Fusobacterium nucleatum Lipopolysaccharides O-Antigen Defines a Novel Siglec-7 Binding Epitope
Fusobacterium nucleatum (Fn) is a Gram-negative bacterium predominantly found in the human oral cavity, occasionally linked to systemic diseases, including colorectal cancer. Bacterial lipopolysaccharides (LPSs) represent one of the possible virulence factors contributing to and promoting disease progression. Fn LPS is recognized by Siglec-7, a sialic acid-binding inhibitory receptor expressed on immune cells and promising novel target for cancer immunotherapy. Through a combined approach of structural biology, biophysics, NMR, and computational methods, we explored the molecular basis of the interaction between Siglec-7 and the LPS fromF. nucleatum ssp polymorphum 10953, whose O-antigen contains peculiar sugars such as the neuraminic acid and the AAT (FucpNAc4N). We discovered a novel Siglec-7 binding epitope within the LPS O-antigen repeating unit, defined by its internal sialic acid and AAT residues. We propose a wing-like movement of the O-antigen, where Siglec-7 BC and CC’ loops alternately engage the O-antigen edges within the binding site, with the BC loop forming more stable interactions. We uncover a novel Fn10953 immune evasion mechanism and highlight Siglec-7 and LPS as novel therapeutic targets for Fn-associated CRC, providing new avenues for intervention.
- 25 September 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (11) , 5367-5380
Open AccessFusobacterium nucleatum Lipopolysaccharides O-Antigen Defines a Novel Siglec-7 Binding Epitope
Fusobacterium nucleatum (Fn) is a Gram-negative bacterium predominantly found in the human oral cavity, occasionally linked to systemic diseases, including colorectal cancer. Bacterial lipopolysaccharides (LPSs) represent one of the possible virulence factors contributing to and promoting disease progression. Fn LPS is recognized by Siglec-7, a sialic acid-binding inhibitory receptor expressed on immune cells and promising novel target for cancer immunotherapy. Through a combined approach of structural biology, biophysics, NMR, and computational methods, we explored the molecular basis of the interaction between Siglec-7 and the LPS fromF. nucleatum ssp polymorphum 10953, whose O-antigen contains peculiar sugars such as the neuraminic acid and the AAT (FucpNAc4N). We discovered a novel Siglec-7 binding epitope within the LPS O-antigen repeating unit, defined by its internal sialic acid and AAT residues. We propose a wing-like movement of the O-antigen, where Siglec-7 BC and CC’ loops alternately engage the O-antigen edges within the binding site, with the BC loop forming more stable interactions. We uncover a novel Fn10953 immune evasion mechanism and highlight Siglec-7 and LPS as novel therapeutic targets for Fn-associated CRC, providing new avenues for intervention.
- Open Access
- 30 April 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (5) , 2257-2269
Molecular Basis of Siglec-7 Recognition by Neisseria meningitidis Serogroup Y CPS: Implications for Immune Evasion
Siglecs, sialic-acid-binding immunoglobulin-like lectins, are key immune cell receptors that recognize sialic acid residues on cell surfaces. Pathogens and tumor cells exploit Siglecs to evade immune responses and modulate immunity, contributing significantly to infectious disease and cancer pathogenesis. Siglec-7, primarily expressed on natural killer (NK) cells, functions as an inhibitory receptor, tightly regulating the immune activity. This study investigates the interaction between Siglec-7 and the capsular polysaccharide (CPS) of Neisseria meningitidis serogroup Y (Men-Y), a bacterium whose sialylated CPS is critical for virulence. We demonstrate that Men-Y CPS binds to inhibitory Siglec-7, potentially dampening immune recognition. We employed a multifaceted approach, combining biochemical and biophysical techniques to dissect this interaction. Enzyme-linked immunosorbent assays (ELISAs) and fluorescence titrations quantified the binding specificity and affinity. Ligand- and protein-based nuclear magnetic resonance (NMR) spectroscopy, coupled with computational modeling, provides detailed molecular insights. We highlight the critical influence of the Men-Y CPS conformation and sialic acid presentation on Siglec-7 binding. The specific arrangement of α-2,6-linked sialic acids on the CPS is crucial for Siglec-7 binding, demonstrating the importance of the CPS 3D structure. Preliminary immunological assays using stimulated U937 cells (a promonocytic cell line) further support the immunomodulatory role of Siglec-7 mediated by Men-Y CPS. These results offer valuable insights into the development of targeted therapeutic strategies against bacterial infections.
- 30 April 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (5) , 2257-2269
Open AccessMolecular Basis of Siglec-7 Recognition by Neisseria meningitidis Serogroup Y CPS: Implications for Immune Evasion
Siglecs, sialic-acid-binding immunoglobulin-like lectins, are key immune cell receptors that recognize sialic acid residues on cell surfaces. Pathogens and tumor cells exploit Siglecs to evade immune responses and modulate immunity, contributing significantly to infectious disease and cancer pathogenesis. Siglec-7, primarily expressed on natural killer (NK) cells, functions as an inhibitory receptor, tightly regulating the immune activity. This study investigates the interaction between Siglec-7 and the capsular polysaccharide (CPS) of Neisseria meningitidis serogroup Y (Men-Y), a bacterium whose sialylated CPS is critical for virulence. We demonstrate that Men-Y CPS binds to inhibitory Siglec-7, potentially dampening immune recognition. We employed a multifaceted approach, combining biochemical and biophysical techniques to dissect this interaction. Enzyme-linked immunosorbent assays (ELISAs) and fluorescence titrations quantified the binding specificity and affinity. Ligand- and protein-based nuclear magnetic resonance (NMR) spectroscopy, coupled with computational modeling, provides detailed molecular insights. We highlight the critical influence of the Men-Y CPS conformation and sialic acid presentation on Siglec-7 binding. The specific arrangement of α-2,6-linked sialic acids on the CPS is crucial for Siglec-7 binding, demonstrating the importance of the CPS 3D structure. Preliminary immunological assays using stimulated U937 cells (a promonocytic cell line) further support the immunomodulatory role of Siglec-7 mediated by Men-Y CPS. These results offer valuable insights into the development of targeted therapeutic strategies against bacterial infections.
- Open Access
- 24 September 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (18)
Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity
Progress in cytokine engineering is driving therapeutic translation by overcoming these proteins’ limitations as drugs. The IL-2 cytokine is a promising immune stimulant for cancer treatment but is limited by its concurrent activation of both pro-inflammatory immune effector cells and antiinflammatory regulatory T cells, toxicity at high doses, and short serum half-life. One approach to improve the selectivity, safety, and longevity of IL-2 is complexing with anti–IL-2 antibodies that bias the cytokine toward immune effector cell activation. Although this strategy shows potential in preclinical models, clinical translation of a cytokine/antibody complex is complicated by challenges in formulating a multiprotein drug and concerns regarding complex stability. Here, we introduced a versatile approach to designing intramolecularly assembled single-agent fusion proteins (immunocytokines, ICs) comprising IL-2 and a biasing anti–IL-2 antibody that directs the cytokine toward immune effector cells. We optimized IC construction and engineered the cytokine/antibody affinity to improve immune bias. We demonstrated that our IC preferentially activates and expands immune effector cells, leading to superior antitumor activity compared with natural IL-2, both alone and combined with immune checkpoint inhibitors. Moreover, therapeutic efficacy was observed without inducing toxicity. This work presents a roadmap for the design and translation of cytokine/antibody fusion proteins.
- 24 September 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (18)
Open AccessEngineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity
Progress in cytokine engineering is driving therapeutic translation by overcoming these proteins’ limitations as drugs. The IL-2 cytokine is a promising immune stimulant for cancer treatment but is limited by its concurrent activation of both pro-inflammatory immune effector cells and antiinflammatory regulatory T cells, toxicity at high doses, and short serum half-life. One approach to improve the selectivity, safety, and longevity of IL-2 is complexing with anti–IL-2 antibodies that bias the cytokine toward immune effector cell activation. Although this strategy shows potential in preclinical models, clinical translation of a cytokine/antibody complex is complicated by challenges in formulating a multiprotein drug and concerns regarding complex stability. Here, we introduced a versatile approach to designing intramolecularly assembled single-agent fusion proteins (immunocytokines, ICs) comprising IL-2 and a biasing anti–IL-2 antibody that directs the cytokine toward immune effector cells. We optimized IC construction and engineered the cytokine/antibody affinity to improve immune bias. We demonstrated that our IC preferentially activates and expands immune effector cells, leading to superior antitumor activity compared with natural IL-2, both alone and combined with immune checkpoint inhibitors. Moreover, therapeutic efficacy was observed without inducing toxicity. This work presents a roadmap for the design and translation of cytokine/antibody fusion proteins.
- Open Access
- 26 August 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Structure of the human NK cell NKR-P1:LLT1 receptor:ligand complex reveals clustering in the immune synapse
Signaling by the human C-type lectin-like receptor, natural killer (NK) cell inhibitory receptor NKR-P1, has a critical role in many immune-related diseases and cancer. C-type lectin-like receptors have weak affinities to their ligands; therefore, setting up a comprehensive model of NKR-P1-LLT1 interactions that considers the natural state of the receptor on the cell surface is necessary to understand its functions. Here we report the crystal structures of the NKR-P1 and NKR-P1:LLT1 complexes, which provides evidence that NKR-P1 forms homodimers in an unexpected arrangement to enable LLT1 binding in two modes, bridging two LLT1 molecules. These interaction clusters are suggestive of an inhibitory immune synapse. By observing the formation of these clusters in solution using SEC-SAXS analysis, by dSTORM super-resolution microscopy on the cell surface, and by following their role in receptor signaling with freshly isolated NK cells, we show that only the ligation of both LLT1 binding interfaces leads to effective NKR-P1 inhibitory signaling. In summary, our findings collectively support a model of NKR-P1:LLT1 clustering, which allows the interacting proteins to overcome weak ligand-receptor affinity and to trigger signal transduction upon cellular contact in the immune synapse.
- 26 August 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Open AccessStructure of the human NK cell NKR-P1:LLT1 receptor:ligand complex reveals clustering in the immune synapse
Signaling by the human C-type lectin-like receptor, natural killer (NK) cell inhibitory receptor NKR-P1, has a critical role in many immune-related diseases and cancer. C-type lectin-like receptors have weak affinities to their ligands; therefore, setting up a comprehensive model of NKR-P1-LLT1 interactions that considers the natural state of the receptor on the cell surface is necessary to understand its functions. Here we report the crystal structures of the NKR-P1 and NKR-P1:LLT1 complexes, which provides evidence that NKR-P1 forms homodimers in an unexpected arrangement to enable LLT1 binding in two modes, bridging two LLT1 molecules. These interaction clusters are suggestive of an inhibitory immune synapse. By observing the formation of these clusters in solution using SEC-SAXS analysis, by dSTORM super-resolution microscopy on the cell surface, and by following their role in receptor signaling with freshly isolated NK cells, we show that only the ligation of both LLT1 binding interfaces leads to effective NKR-P1 inhibitory signaling. In summary, our findings collectively support a model of NKR-P1:LLT1 clustering, which allows the interacting proteins to overcome weak ligand-receptor affinity and to trigger signal transduction upon cellular contact in the immune synapse.
- Open Access
- 7 April 2022
- Published by Springer Nature in Microbial Cell Factories
- Vol. 21 (1) , 1-16
Protein purification strategies must consider downstream applications and individual biological characteristics
Background: Proteins are used as reagents in a broad range of scientific fields. The reliability and reproducibility of experimental data will largely depend on the quality of the (recombinant) proteins and, consequently, these should undergo thorough structural and functional controls. Depending on the downstream application and the biochemical characteristics of the protein, different sets of specific features will need to be checked. Results: A number of examples, representative of recurrent issues and previously published strategies, has been reported that illustrate real cases of recombinant protein production in which careful strategy design at the start of the project combined with quality controls throughout the production process was imperative to obtain high-quality samples compatible with the planned downstream applications. Some proteins possess intrinsic properties (e.g., prone to aggregation, rich in cysteines, or a high affinity for nucleic acids) that require certain precautions during the expression and purification process. For other proteins, the downstream application might demand specific conditions, such as for proteins intended for animal use that need to be endotoxin-free. Conclusions: This review has been designed to act as a practical reference list for researchers who wish to produce and evaluate recombinant proteins with certain specific requirements or that need particular care for their preparation and storage.
- 7 April 2022
- Published by Springer Nature in Microbial Cell Factories
- Vol. 21 (1) , 1-16
Open AccessProtein purification strategies must consider downstream applications and individual biological characteristics
Background: Proteins are used as reagents in a broad range of scientific fields. The reliability and reproducibility of experimental data will largely depend on the quality of the (recombinant) proteins and, consequently, these should undergo thorough structural and functional controls. Depending on the downstream application and the biochemical characteristics of the protein, different sets of specific features will need to be checked. Results: A number of examples, representative of recurrent issues and previously published strategies, has been reported that illustrate real cases of recombinant protein production in which careful strategy design at the start of the project combined with quality controls throughout the production process was imperative to obtain high-quality samples compatible with the planned downstream applications. Some proteins possess intrinsic properties (e.g., prone to aggregation, rich in cysteines, or a high affinity for nucleic acids) that require certain precautions during the expression and purification process. For other proteins, the downstream application might demand specific conditions, such as for proteins intended for animal use that need to be endotoxin-free. Conclusions: This review has been designed to act as a practical reference list for researchers who wish to produce and evaluate recombinant proteins with certain specific requirements or that need particular care for their preparation and storage.
- 4 March 2022
- Published by Elsevier
- Vol. 129, 91-133
Natural killer cell-based strategies for immunotherapy of cancer
- 4 March 2022
- Published by Elsevier
- Vol. 129, 91-133
Natural killer cell-based strategies for immunotherapy of cancer